Effects of Latanoprost, Bimatoprost and Travoprost in Patients With Latanoprost-resistant Glaucoma
Unknown status
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
N/A
2009-01-01
Intraocular pressure (IOP) is considered to be the main risk factor for progression of
glaucoma and therefore the main target of therapy. Pharmacologic treatment of glaucoma has
changed considerably during the last decades due to the introduction of prostaglandin
analogues. Three of these are commonly used in North America: latanoprost (Latanoprost T,
Pfizer), Travoprost (Travatan TM, Alcon) and bimatoprost (Lumigan TM, Allergan).
There have been several studies to evaluate their effectiveness. The three seem to be
equivalent, according to the only study that has compared the molecules. Latanoprost is
employed initially, due to its paucity of side effects when compared to the other two
analogues. However, if it is not effective, several studies ahve shown that a result is
possible using either travoprost or bimatoprost. No study has been conducted to date
systematically comparing the three molecules in cases of resistance to latanoprost. In
actuality, the investigators patients will receive treatment identical to current practice
with the exception of the group continuing with latanoprost. Several studies confirm the
benefit of changing prostaglandin analogues if the first has not signficantly decreased the
IOP (Palmberg et al. 2004). Each prostaglandin has unique properties which may cause the
mechanism of action to vary slightly among patients. (cf. Pharmacological Aspects)
The goal of the study is thus to evaluate the efficaciousness of latanoprost, bimatoprost and
travoprost in their IOP-lowering capacity in patients who do not initially respond to
latanoprost.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
